What you need to know about the EpiPen shortage
BY Matt Terry
August 2, 2018
Canada is facing a serious shortage of the adult dose of EpiPens.
Manufacturer Pfizer has said it will not have new stock of the life-saving epinephrine autoinjector until the end of August – and Pfizer’s the only such needle available in the country.
Epinephrine is used by those at risk of experiencing a serious allergic reaction – known as anaphylaxis – from certain kinds of food or insect stings, among other things.
“It reverses the effects of anaphylaxis, which include low blood pressure, shortness of breath and throat or tongue swelling,” says Susan Waserman, a professor of medicine in McMaster’s division of clinical immunology and allergy.
If left untreated, anaphylaxis can be fatal.
Waserman says nearly 2.5M Canadians report having food allergies, while others suffer from allergies to bee stings, latex or certain drugs.
“Summertime is a difficult time for those with allergies to insect stings,” she says. “It’s also a tough time for the parents of those with allergies, because they have less control over their children’s diet outside of school.”
So what can Canadians faced with an EpiPen shortage do to protect themselves?
“Some will likely stock up on two junior doses, which equal an adult dose,” says Waserman. “Studies have also found that epinephrine remains usable beyond its expiry date, and while we don’t usually recommend relying on expired medication, that would be an option here.”
Waserman also points to the need for a long-term solution, which would require more than one supplier of epinephrine autoinjectors in Canada.
“So long as we have only one producer, we’re at risk of these kinds of shortages.”